中国医疗系统在中国以及亚洲、中东和非洲部分地区获得两项新的破伤风和狂犬病生物学专利权。 China Medical System gains exclusive rights to two new biologics for tetanus and rabies in China and parts of Asia, Middle East, and Africa.

中国医疗体系于2025年9月22日宣布,已获得重庆总会开发的两种新型生物治疗(破伤风Vecantoxatug和狂犬病Silevimig)专有权利。 China Medical System announced on September 22, 2025, that it has secured exclusive rights to two innovative biologic treatments—Vecantoxatug for tetanus and Silevimig for rabies—developed by Chongqing Genrix. 这些协定在中国大陆授予商业化权,并在亚太、中东和北非各地授予许可证权。 The agreements grant commercialization rights in mainland China and licensing rights across the Asia-Pacific, Middle East, and North Africa. 破伤风单克隆抗体Vecantoxatug达到了第三阶段试验目标,并获得 " 突破治疗 " 称号,其药物应用于2025年5月被接受。 Vecantoxatug, a monoclonal antibody for tetanus, met its Phase III trial goals and received Breakthrough Therapy designation, with its drug application accepted in May 2025. Silevimig, 一种针对狂犬病的双性抗体,于2025年1月接受审查,并于2025年7月获得对儿科第三阶段试验的批准。 Silevimig, a bispecific antibody for rabies, was accepted for review in January 2025 and received approval for a pediatric Phase III trial in July 2025. 这两种产品都旨在改善安全和获得目前被动免疫方案的机会。 Both products aim to improve safety and accessibility over current passive immunization options. 最初的十年协议除终止外,每10年自动更新一次,支持中国医疗系统扩大其高价值创新疗法组合的战略。 The initial ten-year agreement auto-renews every ten years unless terminated, supporting China Medical System’s strategy to expand its portfolio of high-value, innovative therapies.